MedCity News December 8, 2023
Frank Vinluan

The first gene therapies for sickle cell disease are now approved: Casgevy from Vertex Pharmaceuticals Casgevy and Lyfgenia from Bluebird Bio. Despite the same-day approval, key differences give one of these therapies commercialization advantages over the other.

Gene therapy is now here for patients with sickle cell disease. The FDA on Friday approved treatments from Vertex Pharmaceuticals and Bluebird Bio, each offering a potentially curative treatment for the inherited blood disorder.

Approval for Vertex’s Casgevy came right on the target date for an FDA decision and three weeks after regulators in the United Kingdom made the treatment the first approved CRISPR-based therapy in the world. For Bluebird’s treatment, named Lyfgenia, the approval comes nearly two weeks early. The FDA decisions...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
FDA issues flu vaccine recommendations: 5 respiratory updates
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns

Share This Article